Loading...
XTAI4155
Market cap94mUSD
Dec 25, Last price  
20.80TWD
1D
-0.24%
1Q
-15.21%
Jan 2017
-15.69%
IPO
-24.41%
Name

OK Biotech Co Ltd

Chart & Performance

D1W1MN
XTAI:4155 chart
P/E
1,037.59
P/S
2.57
EPS
0.02
Div Yield, %
4.73%
Shrs. gr., 5y
10.20%
Rev. gr., 5y
1.25%
Revenues
1.19b
-19.65%
280,794,000405,990,000502,536,000656,695,0001,074,281,000633,765,000856,551,0001,040,462,0001,233,076,0001,120,346,0001,241,252,0001,484,413,0001,263,378,0001,483,523,0001,191,985,000
Net income
3m
-97.95%
49,700,00037,736,00072,340,00096,678,000138,205,00071,364,000110,969,00085,201,000126,809,000161,362,000125,760,000129,728,00031,422,000143,462,0002,948,000
CFO
3m
-98.78%
6,950,000-19,515,00093,117,00079,173,00087,085,000-33,834,000289,435,000260,724,000102,768,000128,750,00045,177,000147,700,00021,896,000240,526,0002,933,000
Dividend
Sep 05, 20240.6 TWD/sh
Earnings
Mar 10, 2025

Profile

OK Biotech Co., Ltd. manufactures and sells blood glucose meters worldwide. It also provides nebulizers, glucometers, blood sugar meters, blood glucose test strips, and personal sound amplifiers. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
URL
https://www.okbiotech.com/
IPO date
Dec 30, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,191,985
-19.65%
1,483,523
17.43%
1,263,378
-14.89%
Cost of revenue
1,190,220
1,343,386
1,253,529
Unusual Expense (Income)
NOPBT
1,765
140,137
9,849
NOPBT Margin
0.15%
9.45%
0.78%
Operating Taxes
9,620
38,868
14,718
Tax Rate
545.04%
27.74%
149.44%
NOPAT
(7,855)
101,269
(4,869)
Net income
2,948
-97.95%
143,462
356.57%
31,422
-75.78%
Dividends
(144,640)
(94,934)
(131,850)
Dividend yield
4.49%
2.94%
5.29%
Proceeds from repurchase of equity
270,000
27,242
BB yield
-8.38%
-1.09%
Debt
Debt current
238,868
394,501
333,973
Long-term debt
99,469
392,434
404,017
Deferred revenue
Other long-term liabilities
24
24
7,425
Net debt
(373,619)
(298,005)
(374,111)
Cash flow
Cash from operating activities
2,933
240,526
21,896
CAPEX
(429,677)
(294,241)
(86,463)
Cash from investing activities
(358,382)
(294,230)
(174,460)
Cash from financing activities
82,063
50,269
185,694
FCF
(155,399)
(92,469)
(302,940)
Balance
Cash
365,340
636,644
644,635
Long term investments
346,616
448,296
467,466
Excess cash
652,357
1,010,764
1,048,932
Stockholders' equity
1,538,388
1,264,038
1,148,287
Invested Capital
2,075,736
1,582,552
1,397,240
ROIC
6.80%
ROCE
0.06%
5.40%
0.40%
EV
Common stock shares outstanding
128,403
132,380
120,402
Price
25.10
2.74%
24.43
17.96%
20.71
-13.35%
Market cap
3,222,915
-0.34%
3,234,044
29.70%
2,493,523
2.98%
EV
2,846,541
2,937,826
2,117,908
EBITDA
77,312
208,019
65,731
EV/EBITDA
36.82
14.12
32.22
Interest
8,997
11,424
8,077
Interest/NOPBT
509.75%
8.15%
82.01%